GENETICS

SOPHiA GENETICS Reports First Quarter 2024 Results

Retrieved on: 
星期二, 五月 7, 2024
Liquid biopsy, Table, Mayo Clinic, Cancer, NHS, Health equity, COVID, Average cost, Book of Wisdom, Breast cancer, FY, GENETICS, Traction, Sophia Genetics, Research, Forecasting, Growth, SOPHIA, NGS, Public expenditure, Algorithm, Patient, MSK, Eastern Time Zone, Acquisition, Medicine, Pension, COVID-19, AstraZeneca, Constant, Central European Time, Pharmaceutical industry

BOSTON and ROLLE, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • BOSTON and ROLLE, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2024.
  • SOPHiA GENETICS will host a conference call and live webcast to discuss the first quarter 2024 results on Tuesday, May 7, 2024, at 8:00 a.m. (08:00) Eastern Time / 2:00 p.m. (14:00) Central European Time.
  • The call will be webcast live on the SOPHiA GENETICS Investor Relations website, ir.sophiagenetics.com.
  • Additionally, an audio replay of the conference call will be available on the SOPHiA GENETICS website after its completion.

SOPHiA GENETICS to Announce Financial Results for First Quarter 2024 on May 7, 2024

Retrieved on: 
星期二, 四月 23, 2024
GENETICS

BOSTON and ROLLE, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter of fiscal year 2024 before U.S. markets open on Tuesday, May 7, 2024.

Key Points: 
  • BOSTON and ROLLE, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter of fiscal year 2024 before U.S. markets open on Tuesday, May 7, 2024.
  • On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET.
  • The call will be webcast live on the SOPHiA GENETICS Investor Relations website .
  • Additionally, a replay will be available on the website after its completion.

SOPHiA GENETICS Announces Syndicate Bio as First Liquid Biopsy Customer in Africa

Retrieved on: 
星期二, 四月 23, 2024
Neoplasm, Sophia Genetics, Cancer, Genomics, Health equity, Travel, GENETICS, Partnership, Research, NGS, Genetics, Data, Patient, MSK, Biopsy, Clinical trial, Medicine, Drug discovery, AstraZeneca, Liquid biopsy, Pharmaceutical industry

BOSTON and ROLLE, Switzerland, April 23, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Nigeria-based Syndicate Bio has signed on to implement MSK-ACCESS® powered with SOPHiA DDM™. Syndicate Bio is the first lab in Africa to adopt the MSK-ACCESS® assay via the SOPHiA DDM™ Platform, and the first company to make comprehensive genomic profiling and liquid biopsy widely available to patients throughout the entire continent. The implementation of this new technology will further existing work from SOPHiA GENETICS, Memorial Sloan Kettering Cancer Center (MSK), and Syndicate Bio to advance health equity on a global scale.

Key Points: 
  • Syndicate Bio is the first lab in Africa to adopt the MSK-ACCESS® assay via the SOPHiA DDM™ Platform, and the first company to make comprehensive genomic profiling and liquid biopsy widely available to patients throughout the entire continent.
  • The implementation of this new technology will further existing work from SOPHiA GENETICS, Memorial Sloan Kettering Cancer Center (MSK), and Syndicate Bio to advance health equity on a global scale.
  • There are roughly 1 million new cancer patients each year in Africa and currently, comprehensive genomic profiling and liquid biopsy testing options are not widely available.
  • "Partnering with SOPHiA Genetics to bring MSK-ACCESS® powered with SOPHiA DDM™ to our lab is a monumental step in accelerating the cancer treatment and research landscape across Africa, beginning in Nigeria.

SOPHiA GENETICS Announces Unilabs is using its AI Technology to Detect Homologous Recombination Deficiency (HRD)

Retrieved on: 
星期三, 四月 17, 2024
HRD, Sophia Genetics, Laboratory, GENETICS, Machine learning, Artificial intelligence, NGS, HRR, DNA, Science, Patient, Neoplasm, Medicine, Ovarian cancer, FAMH

BOSTON and ROLLE, Switzerland, April 17, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Unilabs, one of the largest diagnostic providers in Europe, and the only provider to offer laboratory, imaging and pathology specialties within one group, is live on the SOPHiA DDM™ Platform. Unilabs will use SOPHiA GENETICS' technology to test for HRD-status in solid tumors and provide expedited analysis across its network in Switzerland.

Key Points: 
  • Unilabs will use SOPHiA GENETICS' technology to test for HRD-status in solid tumors and provide expedited analysis across its network in Switzerland.
  • Founded in 1987 in Switzerland, Unilabs conducts more than 221 million tests annually across its laboratories, imaging centers, and collection centers.
  • "SOPHiA GENETICS' AI-based technology is at the forefront of where precision medicine is going – blending science and technology to deliver the best possible outcomes for patients.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.com or connect on X , LinkedIn , Facebook , and Instagram .

SOPHiA GENETICS and Strand Life Sciences Announce New Strategic Partnership

Retrieved on: 
星期四, 四月 4, 2024
Genomics, Health, Organization, Algorithm, Entrepreneurship, Partnership, Sophia Genetics, GENETICS, Strand Life Sciences, Medicine, Cancer, Pharmaceutical industry

BOSTON and ROLLE, Switzerland, April 4, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced a strategic partnership with Strand Life Sciences, a pioneer in bioinformatics and diagnostics, to deliver innovative solutions that will fuel the use of precision medicine globally. The new collaboration will leverage the industry-leading strengths from both companies to provide access to advanced genomics technologies, cutting-edge bioinformatics services and innovative diagnostics solutions.

Key Points: 
  • Headquartered in Bangalore, India, Strand is a life sciences technology company with expertise in bioinformatics, laboratory assays, clinical research and software development.
  • "Strand and SOPHiA GENETICS have a shared vision to improve patient health outcomes through precision medicine," said Jurgi Camblong, PhD., CEO and Co-founder of SOPHiA GENETICS.
  • With their sophisticated technologies and bioinformatics expertise, SOPHiA GENETICS and Strand will jointly deepen their value propositions.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on X , LinkedIn , Facebook , and Instagram .

SOPHiA GENETICS and Strand Life Sciences Announce New Strategic Partnership

Retrieved on: 
星期四, 四月 4, 2024
Genomics, Health, Organization, Algorithm, Entrepreneurship, Partnership, Sophia Genetics, GENETICS, Strand Life Sciences, Medicine, Cancer, Pharmaceutical industry

BOSTON and ROLLE, Switzerland, April 4, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced a strategic partnership with Strand Life Sciences, a pioneer in bioinformatics and diagnostics, to deliver innovative solutions that will fuel the use of precision medicine globally. The new collaboration will leverage the industry-leading strengths from both companies to provide access to advanced genomics technologies, cutting-edge bioinformatics services and innovative diagnostics solutions.

Key Points: 
  • Headquartered in Bangalore, India, Strand is a life sciences technology company with expertise in bioinformatics, laboratory assays, clinical research and software development.
  • "Strand and SOPHiA GENETICS have a shared vision to improve patient health outcomes through precision medicine," said Jurgi Camblong, PhD., CEO and Co-founder of SOPHiA GENETICS.
  • With their sophisticated technologies and bioinformatics expertise, SOPHiA GENETICS and Strand will jointly deepen their value propositions.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on X , LinkedIn , Facebook , and Instagram .

Laboratorio Barnafi-Krause is Live on SOPHiA DDM™

Retrieved on: 
星期二, 四月 2, 2024
Diagnosis, CLL, Leukemia, Incidence, Technical, Patient, NGS, Research, Death, GENETICS, Sophia Genetics, Unit production manager, Chronic lymphocytic leukemia, Bone marrow, Pharmaceutical industry

BOSTON and ROLLE, Switzerland, April 2, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Laboratorio Barnafi-Krause is live on the SOPHiA DDM™ Platform. Laboratorio Barnafi-Krause, located in Chile, has implemented SOPHiA GENETICS' technology to help elevate its testing and analysis of blood cancers and diseases, including Leukemia.

Key Points: 
  • BOSTON and ROLLE, Switzerland, April 2, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Laboratorio Barnafi-Krause is live on the SOPHiA DDM™ Platform.
  • Laboratorio Barnafi-Krause, located in Chile, has implemented SOPHiA GENETICS' technology to help elevate its testing and analysis of blood cancers and diseases, including Leukemia.
  • With the SOPHiA DDM™ Platform, Laboratorio Barnafi-Krause will offer tailored NGS-based workflows that enable accurate and sensitive characterization of the complex mutational landscape associated with blood disorders.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on X , LinkedIn , Facebook , and Instagram .

SOPHiA GENETICS Announces First Homologous Recombination Deficiency (HRD) Customer in Canada

Retrieved on: 
星期三, 三月 20, 2024
Ovarian cancer, Gene, Mutation, BRCA, Genetic testing, Patient, NGS, Research, DNA, Guideline, AI, University, Cancer, Hope, Quality of life, GENETICS, Oncology, Medicine, Clinical trial, Sophia Genetics, HRD, HRR, Pharmaceutical industry

BOSTON and ROLLE, Switzerland, March 20, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced the University of Saskatchewan (USask) as its first HRD customer in Canada. USask will implement the SOPHiA DDM™ Platform for use in its cutting-edge clinical trial, which aims to substantially improve the quality of life for ovarian cancer patients through expanded genetic testing. This is the first clinical trial in Canada designed to improve ovarian cancer treatment decisions and inspire guideline changes to increase access to advanced testing.

Key Points: 
  • BOSTON and ROLLE, Switzerland, March 20, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced the University of Saskatchewan (USask) as its first HRD customer in Canada.
  • This is the first clinical trial in Canada designed to improve ovarian cancer treatment decisions and inspire guideline changes to increase access to advanced testing.
  • It's exactly what we at SOPHiA GENETICS are working so hard to make available to clinician researchers around the world," said John Carey, Managing Director, NORAM, SOPHiA GENETICS.
  • The SOPHiA DDM™ Comprehensive Profiling Solution coupled with SOPHiA GENETICS' proprietary deep learning algorithm, GIInger™, will provide USask with a widespread look at potential mutations for each patient.

Microsoft and NVIDIA announce major integrations to accelerate generative AI for enterprises everywhere

Retrieved on: 
星期一, 三月 18, 2024
Cloud, Microsoft, Sanofi, Microsoft Azure, GTC, Organization, Natural language processing, GPU, Triton, Broad Institute, Public health, Biotechnology, Mass General Brigham, MIT, InfiniBand, Harvard University, SAN, MIG, 3D, Microsoft Power BI, AI, University, First officer (aviation), Software, GENETICS, AUC, VM, LLM, Cloud computing, VMS, Creativity, NIM, Flywheel, NVIDIA, Health, Mass, Silicon, Video game

New NVIDIA generative AI Microservices for enterprise, developer and healthcare applications coming to Microsoft Azure AI

Key Points: 
  • New NVIDIA generative AI Microservices for enterprise, developer and healthcare applications coming to Microsoft Azure AI
    REDMOND, Wash. and SAN JOSE, Calif., March 18, 2024 /PRNewswire/ -- At GTC on Monday, Microsoft Corp. and NVIDIA expanded their longstanding collaboration with powerful new integrations that leverage the latest NVIDIA generative AI and Omniverse™ technologies across Microsoft Azure, Azure AI services, Microsoft Fabric and Microsoft 365.
  • "AI is transforming our daily lives — opening up a world of new opportunities," said Jensen Huang, founder and CEO of NVIDIA.
  • At NVIDIA GTC , Microsoft is demonstrating a preview of what is possible using Omniverse Cloud APIs on Microsoft Azure.
  • NVIDIA GPUs and NVIDIA Triton Inference Server™ help serve AI inference predictions in Microsoft Copilot for Microsoft 365.

Microsoft announces collaboration with NVIDIA to accelerate healthcare and life sciences innovation with advanced cloud, AI and accelerated computing capabilities

Retrieved on: 
星期一, 三月 18, 2024
Cloud, Microsoft, MSFT, Genomics, PIN, Microsoft Azure, Organization, Public, Informatics, Public health, Biotechnology, Radiology, Health, Drug discovery, Intelligence, COVID-19, Patient, Research, Cancer, Sophia Genetics, AI, University, Software, GENETICS, Cloud computing, Drug development, Nuance, Catalog, Multimedia, Data management, NVIDIA, DSM-IV codes, Medical device

REDMOND, Wash., March 18, 2024 /PRNewswire/ -- Microsoft Corp. is expanding its collaboration with NVIDIA to bring the power of generative AI, the cloud and accelerated computing to healthcare and life sciences organizations.

Key Points: 
  • REDMOND, Wash., March 18, 2024 /PRNewswire/ -- Microsoft Corp. is expanding its collaboration with NVIDIA to bring the power of generative AI, the cloud and accelerated computing to healthcare and life sciences organizations.
  • The collaboration will bring together the global scale, security and advanced computing capabilities of Microsoft Azure with NVIDIA DGX Cloud and the NVIDIA Clara suite of computing platforms, software and services to help healthcare and life sciences organizations accelerate innovation and improve patient care.
  • "The convergence of AI, cloud computing and healthcare is set to transform patient care," said Kimberly Powell, vice president of healthcare, NVIDIA.
  • Microsoft is collaborating with NVIDIA to make a future suite of NVIDIA healthcare microservices available on Azure AI for optimized inference and fine-tuning.